Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1;42(5):147.
doi: 10.1007/s12032-025-02681-w.

Mesoporous polydopamine nanoparticles coated with metal-polyphenol networks for demethylation therapy of lung cancer

Jingsi Wang  1 , Xufeng Deng  1 , Manyuan Li  1 , Xiaobing Liu  2 , Quanxing Liu  3   4
Affiliations

Mesoporous polydopamine nanoparticles coated with metal-polyphenol networks for demethylation therapy of lung cancer

Jingsi Wang et al. Med Oncol. .

Abstract

The treatment of lung cancer with azacitidine (AZA) is urgently in need of a novel delivery material due to its limitations, including a short half-life, high cytotoxicity, and poor tumor targeting. To overcome these limitations, the coordination of Gallic acid-catechin-gallate with Fe3+ and its encapsulation on the surface of mPDA loaded with AZA (mA@EF) was prepared. mA@EF exhibited a uniform distribution of regular spherical particles with good stability and drug release properties. In cell experiments, mA@EF effectively inhibited cell viability, promoted cellular uptake, and downregulated the expression of DNA methyltransferases. Moreover, mA@EF demonstrated good biosafety. In animal experiments, mA@EF showed strong tumor-targeting and retention activity, and significantly inhibited the growth of tumor. This discovery provided a feasible dosing regimen for AZA treatment in lung cancer patients.

Keywords: Azacitidine; Biosafety; DNA methyltransferase; Tumor targeting; mA@EF.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interest: The authors declare no competing interests. Ethical approval: All experimental procedures adhered to ARRIVE 2.0 guidelines and were approved by the Experimental Animal Welfare and Ethics Review Committee of Army Medical University (AMUWEC20245329). Consent to participate: All experimental procedures adhered to ARRIVE 2.0 guidelines and were approved by the Experimental Animal Welfare and Ethics Review Committee of Army Medical University (AMUWEC20245329). Consent for publication: NA.

References

    1. Fernandes MGO, Dias M, Santos R, Ravara S, Fernandes P, Firmino-Machado J, et al. Recommendations for the implementation of a national lung cancer screening program in Portugal-a consensus statement. Pulmonology. 2024;30:625–35. https://doi.org/10.1016/j.pulmoe.2024.04.003 . - DOI - PubMed
    1. Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20:624–39. https://doi.org/10.1038/s41571-023-00798-3 . - DOI - PubMed
    1. Chen Q, Zheng X, Cheng W, Li J. Landscape of targeted therapies for lung squamous cell carcinoma. Front Oncol. 2024;14:1467898. https://doi.org/10.3389/fonc.2024.1467898 . - DOI - PubMed - PMC
    1. Scott LJ. Azacitidine: a review in myelodysplastic syndromes and acute myeloid leukaemia. Drugs. 2016;76:889–900. https://doi.org/10.1007/s40265-016-0585-0 . - DOI - PubMed
    1. Yang Y, Li J, Geng Y, Liu L, Li D. Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes. J Clin Lab Anal. 2021;35:e23597. https://doi.org/10.1002/jcla.23597 . - DOI - PubMed

LinkOut - more resources